We are live on ! Find out more
ETNB

89bio

Delisted

ETNB was delisted on the 29th of October, 2025.

106 hedge funds and large institutions have $589M invested in 89bio in 2022 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

579% more call options, than puts

Call options by funds: $5.79M | Put options by funds: $852K

180% more capital invested

Capital invested by funds: $210M → $589M (+$378M)

117% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 18

65% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 20

23% more funds holding

Funds holding: 86106 (+20)

2.99% less ownership

Funds ownership: 102.48%99.5% (-3%)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
106
Holders Change
+20
Holders Change %
+23.26%
% of All Funds
1.7%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
39
Increased
33
Reduced
20
Closed
18
Calls
$5.79M
Puts
$852K
Net Calls
+$4.94M
Net Calls Change
+$2.92M
Name Holding Trade Value Shares
Change
Change in
Stake
AG
26
Artal Group
Luxembourg
$5.09M +$3.6M +400,000 New
OCA
27
Octagon Capital Advisors
New York
$4.84M +$3.42M +380,000 New
SCM
28
Soleus Capital Management
Connecticut
$4.82M +$441K +49,000 +15%
Geode Capital Management
29
Geode Capital Management
Massachusetts
$4.38M +$919K +102,148 +42%
PHP
30
Parkman Healthcare Partners
Connecticut
$4.24M +$971K +107,880 +48%
DCM
31
DAFNA Capital Management
California
$4.13M -$2.98M -330,689 -50%
NM
32
Newtyn Management
New York
$3.95M
CSS
33
Cubist Systematic Strategies
Connecticut
$3.7M +$2.23M +248,208 +580%
EI
34
EAM Investors
California
$3.51M +$767K +85,225 +45%
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$2.94M +$2.08M +231,250 New
Renaissance Technologies
36
Renaissance Technologies
New York
$2.74M -$167K -18,600 -8%
PHS
37
Pekin Hardy Strauss
Illinois
$2.48M -$1.19M -132,398 -40%
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$2.44M +$543K +60,358 +46%
LCM
39
Laurion Capital Management
New York
$2.38M
SFM
40
Sphera Funds Management
Israel
$2.3M -$4.3M -478,184 -73%
JP Morgan Chase
41
JP Morgan Chase
New York
$1.83M -$718K -79,809 -36%
AllianceBernstein
42
AllianceBernstein
Tennessee
$1.67M +$1.18M +130,877 New
EGI
43
EAM Global Investors
California
$1.6M +$1.13M +125,394 New
PMAM
44
Picton Mahoney Asset Management
Ontario, Canada
$1.42M +$18K +2,000 +2%
Morgan Stanley
45
Morgan Stanley
New York
$1.34M -$245K -27,254 -21%
State Street
46
State Street
Massachusetts
$1.34M +$379K +42,100 +67%
RJFSA
47
Raymond James Financial Services Advisors
Florida
$1.31M -$517K -57,417 -36%
Jane Street
48
Jane Street
New York
$1.29M +$733K +81,441 +411%
BCM
49
Bridgeway Capital Management
Texas
$1.17M
BFM
50
Boothbay Fund Management
New York
$1.13M +$475K +52,775 +148%

ETNB Hedge Fund Activity: Q4 2022 in Review

106 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q4 2022, worth a combined $589M — up 180% from $210M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ETNB positions and 18 closed out — a net gain of 21 holders — while 33 added to existing stakes and 20 trimmed.

The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $22.9M. The largest seller was BVF Inc, exiting entirely with an estimated $18.2M sold.

  • 106 institutional investors held 89bio (ETNB) as of Q4 2022, up from 86 in Q3 2022.
  • Funds reported $589M of 89bio stock for Q4 2022, up 180% quarter-over-quarter.
  • 39 funds opened new 89bio positions in Q4 2022 and 18 closed out, a net change of +21 holders.
  • The largest 89bio buyer in Q4 2022 was Cormorant Asset Management, an estimated $22.9M added.
  • The largest 89bio seller in Q4 2022 was BVF Inc, an estimated $18.2M sold.

Based on aggregated 13F filings for Q4 2022.